It was nice to see a few of articles addressing Still’s Disease these past two days; I’ll post links to them here but, as always, they can be found in the Articles section too.
The first article addresses the news that the safety and efficacy of Tocilizumab has been found to be sustained at the two year mark, meaning that improvements seen in the initial trials were still felt by the patient after two years.
The second article is the story of a young Australian girl with Still’s Disease, who has found some relief with Tocilizumab. The drug was only approved for use in children this month in Australia; they can now access the drug on compassionate grounds, but adults are still waiting for the drug to qualify for subsidy and can only access it privately.
Lastly, is an article about a young woman with Still’s Disease, who has also been given a new lease of life thanks to Tocilizumab.
Certainly seems to be the drug of choice right now.